First Occurrence of an Escherichia coli Clinical Isolate Producing the VIM-1/VIM-2 Hybrid Metallo-β-Lactamase VIM-12

Gram-negative bacteria producing VIM-type metallo-β-lactamases (MBLs) are increasingly isolated worldwide (8). The VIM group includes at least 13 variants, clustered into three evolutionary lineages, driven by VIM-1, VIM-2, and VIM-7 (www.lahey.org/studies/other.asp#table1). blaVIM-12 is a recently identified blaVIM-1/VIM-2 hybrid gene, originally found in 2005 in a Klebsiella pneumoniae clinical isolate from Greece and ranked as intermediate between blaVIM-1 and blaVIM-2 (6). Its gene cassette resides in a class 1 integron, designated In-h12 (6); it has not since been detected in other gram-negative species. Kinetic parameters of the purified VIM-12 enzyme have not been described. We document herein the identification of the blaVIM-12 gene in an Escherichia coli clinical isolate.

E. coli strain 28 was recovered in February 2006 from a decubitus ulcer infection of an 85-year-old male hospitalized at Hipposkaron General Hospital, Thessaloniki, Greece, for lower respiratory tract infection. MICs of several β-lactams, aminoglycosides, ciprofloxacin, ticarcillin, and colistin were determined by using Etest (AB Biokin, Solna, Sweden). The isolate was phenotypically screened for MBL production using E. coli (AB Diagnostik) and the imipenem-EDTA double disc synergy test (DDST) (5). Pseudomonas aeruginosa ATCC 27853 was used as a control in all susceptibility assays.

PCR detection of various genes encoding MBLs, extended-spectrum beta-lactamases, and AmpC enzymes, including blaVIM, blaIMI, blaTEM, blaSHV, blaGES, and blaCTX-M, and blaCMY-LAT, and PCR integron mapping were performed as described previously (6), followed by DNA sequencing.

Filter mating experiments were performed using E. coli 26R793 (Rif+) as the recipient. Selection of transconjugants was made on MacConkey agar plates containing rifampin (100 μg/ml) and ceftazidime (2 to 4 μg/ml). Plasmid isolation was performed using the ChargeSwitch Plasmid ER minikit (InGen Corporation, Carlsbad, CA) and a standard alkaline lysis protocol, using E. coli 39R861 as the standard plasmid control. Restriction fragment length polymorphism (RFLP) of the plasmid extract of E. coli strain 28 and the transconjugant derived from Klebsiella pneumoniae 2873 carrying VIM-12 in plasmid p2873 (6) was performed using BamHI. The location of the blaVIM gene was determined as described previously (3) by Southern blotting of unsheared genomic DNA, followed by gene-specific hybridization using a digoxigenin-labeled blaVIM-1 probe (7).

E. coli strain 28 was susceptible to imipenem and meropenem (MICs, 1 and 0.25 μg/ml, respectively), aztreonam, ciprofloxacin, and colistin but resistant to all other antimicrobials tested (Table 1). The presence of MBL was indicated by positive DDST and Etest MBL. PCR for β-lactamase genes showed that E. coli strain 28 was positive for blaVIM and blaCMY-LAT but negative for the remaining genes. PCR assays using primers 5’CS and 3’CS in several combinations with primers blaVIM and aacA and nucleotide sequencing revealed an integron structure identical with that of integron In-h12, originally found in the blaVIM-12-producing K. pneumoniae (GenBank accession number DQ143913) (6).

Repeated mating experiments yielded, at a median frequency of 1.8 × 10-2 per donor cell, transconjugant colonies that had elevated MICs of penicillins, cephalosporins, and aminoglycosides but not of carbapenems and tetracycline (Table 1). Plasmid analysis of both clinical and transconjugant colonies showed a single plasmid of approximately 70 kb. PCR specific for blaVIM and blaCMY-LAT in several transconjugant colonies was positive only for the latter gene. RFLP analysis with BamHI showed that the conjugative plasmid of E. coli strain 28 had a different restriction pattern from that of p2873 (6), tested in parallel. The location of In-h12 in the chromosome was indicated by hybridization of the unsheared genomic DNA with the blaVIM-1 probe.

Production of VIM-12, a VIM-1/VIM-2 hybrid MBL, is documented here for the first time for an E. coli isolate after its original detection in K. pneumoniae. It is noteworthy that several blaVIM-1/VIM-2-producing K. pneumoniae strains have been identified in the same hospital since the original detection in 2005 (unpublished data), indicating a rather wide dissemination of this gene among our K. pneumoniae isolates. E. coli strain 28 carried an integron identical to In-h12, although not lying in the transposable plasmid p2873, which harbored blaVIM-12 in K. pneumoniae (6). It could be speculated here that the integron In-h12 containing the blaVIM-1/VIM-2 hybrid gene blaVIM-12 has arisen within our hospital settings, where blaVIM-1- and blaVIM-2-carrying gram-negative pathogens are common (1, 2, 4, 7). Alternatively, the blaVIM-12 gene might be independent and have a wide natural distribution in bacterial populations, as was observed previously for other blaVIM genes (8).

TABLE 1. Susceptibilities of strain EC28 and its respective transconjugant carrying pEC28

<table>
<thead>
<tr>
<th>Antibiotic(s)</th>
<th>MIC (μg/ml) of antibiotic(s) for:</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. coli 28</td>
<td>Transconjugant strain (pEC28)</td>
</tr>
<tr>
<td>(VIM-12)</td>
<td>(VIM-12)</td>
</tr>
<tr>
<td>Imipenem</td>
<td>1</td>
</tr>
<tr>
<td>Meropenem</td>
<td>0.25</td>
</tr>
<tr>
<td>Ertapenem</td>
<td>0.5</td>
</tr>
<tr>
<td>Aztreonam</td>
<td>1</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>&gt;32</td>
</tr>
<tr>
<td>Cefepime</td>
<td>12</td>
</tr>
<tr>
<td>Cefazidime</td>
<td>&gt;256</td>
</tr>
<tr>
<td>Cefoxime</td>
<td>&gt;256</td>
</tr>
<tr>
<td>Amoxicillin</td>
<td>&gt;256</td>
</tr>
<tr>
<td>Amikacin</td>
<td>&gt;256</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>&gt;256</td>
</tr>
<tr>
<td>Piperacillin</td>
<td>&gt;256</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>0.047</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>&gt;256</td>
</tr>
<tr>
<td>Trimethoprim-sulfamethoxazole</td>
<td>0.094</td>
</tr>
</tbody>
</table>

* | CLA, clavulanic acid (2 μg/ml); TZB, tazobactam (4 μg/ml).

REFERENCES


Copyright © 2007, American Society for Microbiology. All Rights Reserved.


Alexandros Ikonomidis
Maria Labrou
Department of Medical Microbiology
University Hospital of Larissa
41110 Larissa, Greece

Zoe Afkou
Department of Microbiology
Ippokration Hospital of Thessaloniki
Thessaloniki, Greece

Antonios N. Maniatis
Department of Medical Microbiology
University Hospital of Larissa
41110 Larissa, Greece

Danai Sofianou
Department of Microbiology
Ippokration Hospital of Thessaloniki
Thessaloniki, Greece

Athanassios Tsakris
Department of Microbiology
University of Athens
11527 Athens, Greece

Spyros Pournaras*
Department of Medical Microbiology
University of Larissa
41110 Larissa, Greece

*Phone: (30) 2410 682929
Fax: (30) 2410 681570
E-mail: pournaras@med.uth.gr

*Published ahead of print on 21 May 2007.